OTLK
Price:
$1.58
Market Cap:
$65.00M
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Hua...[Read more]
Industry
Biotechnology
IPO Date
2016-06-14
Stock Exchange
NASDAQ
Ticker
OTLK
According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 178.08%. This represents a change of 317.39% compared to the average of 42.66% of the last 4 quarters.
The mean historical ROE of Outlook Therapeutics, Inc. over the last ten years is -83.48%. The current 178.08% ROE has changed -313.33% with respect to the historical average. Over the past ten years (40 quarters), OTLK's ROE was at its highest in in the June 2023 quarter at 375.70%. The ROE was at its lowest in in the June 2016 quarter at -1428.35%.
Average
-83.48%
Median
135.52%
Minimum
-1246.96%
Maximum
1.03%
Discovering the peaks and valleys of Outlook Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 409.30%
Maximum Annual ROE = 1.03%
Minimum Annual Increase = -489.00%
Minimum Annual ROE = -1246.96%
| Year | ROE | Change |
|---|---|---|
| 2025 | 193.94% | 88.05% |
| 2024 | 103.13% | -74.75% |
| 2023 | 408.53% | -154.04% |
| 2022 | -756.04% | -34.48% |
| 2021 | -1153.96% | -7.46% |
| 2020 | -1246.96% | -489.00% |
| 2019 | 320.56% | 121.69% |
| 2018 | 144.60% | 14.37% |
| 2017 | 126.43% | -87.66% |
| 2016 | 1.03% | 409.30% |
The current ROE of Outlook Therapeutics, Inc. (OTLK) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
235.20%
5-year avg
-240.88%
10-year avg
-83.48%
Outlook Therapeutics, Inc.’s ROE is greater than Spruce Biosciences, Inc. (-155.40%), less than NRx Pharmaceuticals, Inc. (107.73%), greater than Cue Biopharma, Inc. (-98.30%), greater than Werewolf Therapeutics, Inc. (-208.23%), greater than IO Biotech, Inc. (-465.36%), less than OS Therapies Incorporated (3.21%), greater than Coeptis Therapeutics, Inc. (-89.63%), greater than Equillium, Inc. (-61.43%), greater than Century Therapeutics, Inc. (-53.23%), greater than Medicus Pharma Ltd. Common Stock (-4086.31%),
| Company | ROE | Market cap |
|---|---|---|
| -155.40% | $71.84M | |
| 107.73% | $68.62M | |
| -98.30% | $74.79M | |
| -208.23% | $17.07M | |
| -465.36% | $885.69K | |
| 3.21% | $85.96M | |
| -89.63% | $57.35M | |
| -61.43% | $108.34M | |
| -53.23% | $198.24M | |
| -4086.31% | $10.08M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Outlook Therapeutics, Inc.'s ROE?
How is the ROE calculated for Outlook Therapeutics, Inc. (OTLK)?
What is the highest ROE for Outlook Therapeutics, Inc. (OTLK)?
What is the 3-year average ROE for Outlook Therapeutics, Inc. (OTLK)?
What is the 5-year average ROE for Outlook Therapeutics, Inc. (OTLK)?
How does the current ROE for Outlook Therapeutics, Inc. (OTLK) compare to its historical average?